In this scenario, the current work analyzes the mechanisms underlying the differential regulation of ACSL4 in TNBC and ERα-positive breast cancer cells, which may allow to identify therapeutic targets and possible future drug combinations. This evidence concerns the gene ESR1 and breast carcinoma.